Biosimilars – Market Events And Forecast – Nephrology

In 2019, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled almost $3.98 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029 forecast period, biosimilars of Aranesp / Nesp (darbepoetin alfa) and Mircera (methoxy polyethylene glycol-epoetin beta) are expected to enter the major markets, alongside currently available epoetin alfa biosimilars, further increasing the need for companies to set competitive pricing to either gain or maintain ESA patient shares. We present our ESA forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.

Table of contents

  • Biosimilars - Market Events And Forecast - Nephrology
    • Market Forecast in the Major Pharmaceutical Markets
      • Major-Market Forecast: Nephrology Biologics (ESAs)
      • Terminology
      • Overarching Forecast Assumptions
        • Overview of ESA Brands in Forecast
          • Biosimilar Entry Assumptions for ESAs
        • Overview of Biosimilar ESA Assumptions
        • Drug-Specific Forecast Assumptions
          • Epogen, Procrit, Eprex, Espo
            • Outlook for Epogen / Procrit / Espo
            • First Major-Market ESA Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Epogen Sales Forecast in the United States: 2019-2029
            • Espo Sales Forecast in Japan: 2019-2029
            • Procrit Sales Forecast in the United States: 2019-2029
            • Eprex Sales Forecast in the EU5: 2019-2029
          • Aranesp / Nesp
            • Outlook for Aranesp / Nesp
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Aranesp Sales Forecast in the United States: 2019-2029
            • Aranesp Sales Forecast in the EU5: 2019-2029
            • Nesp Sales Forecast in Japan: 2019-2029
          • Mircera
            • Outlook for Mircera
            • First Major-Market Biosimilar Entrants
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Mircera Sales Forecast in the United States: 2019-2029
            • Mircera Sales Forecast in the EU5: 2019-2029
            • Mircera Sales Forecast in Japan: 2019-2029

      launch Related Market Assessment Reports